Is Barinthus Biotherapeutics plc (BRNS) a Buy, Sell, or Hold?
Barinthus Biotherapeutics plc
NASDAQ:BRNS
$0.6122 USD
$0.0 (0.36%)
- Volume
- 26.66K
- Average Volume
- 69.38K
- Market Capitalization
- $25.01M
- P/E Ratio
- -0.47
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $2.92
- Year Low
- $0.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.05
| Source | Headline |
|---|---|
|
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws prnewswire.com - 2026-05-12 02:54:00 |
|
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate,. businesswire.com - 2026-05-11 12:08:00 |
|
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company's corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential. globenewswire.com - 2026-04-30 07:30:00 |
